News Search Results
Mar 24, 2026, 07:00 ET Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO® (also known as NEXPOVIO® in certain countries) has received regulatory
More news about: Karyopharm Therapeutics Inc.
Mar 23, 2026, 07:30 ET HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
treatment of cutaneous T-cell lymphoma (CTCL) are being presented at the United States Cutaneous Lymphoma Consortium (USCLC) Workshop (March 26, 2026), which precedes the American Academy of Dermatology (AAD) Annual Meeting. Ellen Kim, MD, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical
More news about: Soligenix
Mar 20, 2026, 05:06 ET Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
List (NRDL), including XPOVIO® monotherapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and XPOVIO® in combination with dexamethasone for the treatment of R/R MM.Taiwan
More news about: Antengene Corporation Limited
Mar 19, 2026, 16:00 ET Curis Provides Fourth Quarter 2025 Business Update
Operational HighlightsTakeAim LymphomaLakshmi Nayak, MD, Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston, presented a poster with updated clinical data in Primary CNS Lymphoma (PCNSL) at the 30th Annual Meeting of
More news about: Curis, Inc.
Mar 19, 2026, 10:01 ET Preimplantation Genetic Testing Market to Reach US$ 1,081.9 Million by 2033 Amid Rising IVF Adoption and Technological Innovation - Persistence Market Research
Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Flow Cytometry, Immunohistochemistry (IHC), Others), Cancer Type (Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Others), End-user, and Regional Analysis from 2026 – 2033
More news about: Persistence Market Research Pvt. Ltd.
Mar 19, 2026, 10:00 ET Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
demand, while Yescarta received a label update removing a limitation around Primary Central Nervous System Lymphoma, making it the only CAR-T therapy in relapsed or refractory large B-cell lymphoma to have that restriction lifted. The company also presented positive pivotal Phase 2 iMMagine-1 data for
More news about: USA News Group
Mar 19, 2026, 07:30 ET Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Topical Hypericin: A Promising Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma" is authored by Brian Poligone, MD, PhD, the founder and Medical Director of the Rochester Skin Lymphoma Medical Group and the Director of Cancer Biology Research for the Rochester General Hospital
More news about: SOLIGENIX, INC.
Mar 17, 2026, 20:43 ET 【AACR 2026】亞盛醫藥宣佈將在2026年美國癌症研究協會年會上公佈四項最新臨床前進展
Multikinase inhibitor olverembatinib (HQP1351) is efficacious and synergizes with BTK inhibitor acalabrutinib in mantle cell lymphoma (MCL) preclinical models多激酶抑制劑奧雷巴替尼（HQP1351）在套細胞淋巴瘤（MCL
More news about: 亞盛醫藥
Mar 17, 2026, 19:00 ET Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data - Including Initial Clinical Trial Results for Lead Immuno-Oncology Candidates SynKIR™-110 and SynKIR™-310 - at AACR Annual Meeting 2026
be released in oral late-breaking presentation; preclinical and initial Phase 1 data from CELESTIAL-301 assessing SynKIR™-310 in B cell Non-Hodgkin Lymphoma to be released in separate poster presentation SynKIR™-110 and SynKIR™-310 are the first multi-chain KIR-CAR-based
More news about: Verismo Therapeutics
Mar 17, 2026, 10:08 ET Cellipont Bioservices and BobcatBio Announce Strategic Collaboration to Advance Macrophage Cell Therapy for Solid Tumors
becoming a preferred therapy across a wide spectrum of solid tumors and lymphomas. Early clinical findings in relapsed or refractory non-Hodgkin lymphoma indicate that RB-1355 is well tolerated with encouraging early signs of activity. Recent clinical data also demonstrated that the therapy can be effectively
More news about: Cellipont Bioservices
Mar 17, 2026, 07:35 ET Knight Therapeutics Anuncia Aprovação de Indicação Adicional para MINJUVI® (tafasitamabe) no Brasil
transformation in follicular lymphoma. Br J Haematol 2012;157:188-196.Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 2020;95:316-327.Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia submissão regulatória suplementar de MINJUVI® (tafasitamabe) para linfoma folicular na Argentina e no México
transformation in follicular lymphoma. Br J Haematol 2012;157:188-196.Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 2020;95:316-327.Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia la aprobación de una indicación adicional para MINJUVI® (tafasitamab) en Brasil
transformation in follicular lymphoma. Br J Haematol 2012;157:188-196.Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 2020;95:316-327.Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia la presentación regulatoria complementaria de MINJUVI® (tafasitamab) para linfoma folicular en Argentina y México
transformation in follicular lymphoma. Br J Haematol 2012;157:188-196.Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 2020;95:316-327.Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the
More news about: Knight Therapeutics Inc.
Mar 12, 2026, 16:27 ET Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026
inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of
More news about: Curis, Inc.
Mar 12, 2026, 10:01 ET Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight
indications such as Breast cancer, Extensive-stage small cell lung cancer (ES-SCLC), Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Follicular Lymphoma, Glioblastoma multiforme, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides
More news about: DelveInsight Business Research, LLP
Mar 10, 2026, 17:31 ET CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
Non-Hodgkin's Lymphoma MarketNon-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the
More news about: DelveInsight Business Research, LLP
Mar 10, 2026, 15:21 ET Checkpoint Inhibitor Refractory Cancer Drugs Market to Reach USD 95,548.35 Million by 2032 Amid Rising Post-Checkpoint Inhibitor Sequencing Demand and Combination Treatment Adoption - Credence Research
Type, the market includes CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor, and Others.By Application, the market includes Hodgkin Lymphoma, Kidney Cancer, Melanoma, Non-Small Cell Lung Cancer, and Others.By Sales Channel, the market includes Hospital Pharmacies, Retail
More news about: Credence Research Inc.
Mar 10, 2026, 08:47 ET Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
tumors.About LYMPHIR™ (denileukin diftitox‑cxdl)LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2
More news about: Citius Oncology, Inc.
Mar 10, 2026, 07:30 ET Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.
More news about: SOLIGENIX, INC.
Mar 10, 2026, 07:30 ET ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
Comprehensive Cancer Center-led multi-center trials of ZYNLONTA in combination with rituximab to treat r/r follicular lymphoma (FL) and as a monotherapy to treat marginal zone lymphoma (MZL) between the end of 2026 and mid-2027. Assuming positive data, the Company intends to assess potential regulatory
More news about: ADC Therapeutics SA
Mar 09, 2026, 09:00 ET Maryland's Former First Lady Yumi Hogan to Receive Prestigious Mendez Award At Maryland International Film Festival - Hagerstown Red Carpet Opening Night March 26th
Hogan, she served as Maryland's First Lady from January 2015 -January 2023.Following Governor Hogan's diagnosis with Stage 3 non-Hodgkin's Lymphoma in 2015 and their family's battle with the disease, Mrs. Hogan has become a vocal advocate for cancer awareness and devoted much of her time to visiting Marylanders
More news about: Maryland International Film Festival-Hagerstown
Mar 09, 2026, 08:00 ET Court Authorizes Notice of Proposed Class Action Settlement for Farmers, Landscapers and Others Exposed to Weed Killers
rights and options. The proposed settlement resolves claims that exposure to Roundup® and other glyphosate-based weed killers causes non-Hodgkin lymphoma (NHL), a blood cancer that can take 10 to 15 years to develop after exposure. Monsanto denies all allegations of wrongdoing and liability. The Court
More news about: Holland Law Firm
Mar 09, 2026, 08:00 ET Court Authorizes Notice of Proposed Class Action Settlement for Farmers, Landscapers and Others Exposed to Weed Killers
rights and options. The proposed settlement resolves claims that exposure to Roundup® and other glyphosate-based weed killers causes non-Hodgkin lymphoma (NHL), a blood cancer that can take 10 to 15 years to develop after exposure. Monsanto denies all allegations of wrongdoing and liability. The Court
More news about: Holland Law Firm
Mar 09, 2026, 08:00 ET 법원, 농민•조경업자 등 제초제 노출 피해자 대상 집단소송 합의안 통지 허가
승인하고, 합의 집단에 포함될 수 있는 개인들에게 권리와 선택 사항을 알리기 위한 포괄적인 통지 프로그램 시행을 승인했다. 이번 합의안은 Roundup® 및 기타 글리포세이트 기반 제초제 노출이 혈액암의 일종인 비호지킨 림프종(Non-Hodgkin Lymphoma, NHL)을 유발했다는 주장과 관련된 청구를 해결하기 위한 것이다. 해당 질병은 노출 후 10~15년이 지나 발병할 수 있다. 몬산토는 모든 위법 행위 및 책임에 대한 의혹을 부인하고 있으며, 법원은 청구의 실체적 타당성에 대해 어떠한 판단도 내리지 않았다.현재
More news about: Holland Law Firm